Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Entheon Biomedical Corp. is a Canada-based biotechnology company that was focused on the research and development of psychedelic-inspired medicines, primarily targeting substance use disorders and addiction. The company operated within the biopharmaceutical and mental health therapeutics industries, with an emphasis on developing regulated pharmaceutical formulations rather than wellness or recreational products. Its core scientific focus centered on N,N-Dimethyltryptamine (DMT) as a potential treatment for opioid and other substance dependencies.
The company’s strategy combined drug development with precision medicine approaches, including genetic testing to personalize addiction treatment. Entheon Biomedical Corp. was incorporated in Canada and became publicly traded on the Canadian Securities Exchange before also trading in the U.S. over-the-counter market under the ticker ENTBF. Public disclosures from 2022 onward indicate that the company significantly reduced or ceased active operations due to capital constraints, and aspects of its current operating status are unclear based on available public information.
Business Operations
Historically, Entheon Biomedical Corp. generated no commercial revenue and operated as a pre-revenue clinical-stage biotechnology company. Its primary business activities involved preclinical research, regulatory planning, and intellectual property development related to psychedelic-based therapeutics. A key operating subsidiary was HaluGen Life Sciences Inc., which focused on genetic testing and analysis intended to identify individuals at higher risk for addiction or adverse reactions to psychedelic compounds.
Operations were primarily research-oriented and based in Canada, with stated intentions to pursue clinical trials in the United States subject to regulatory approvals. As of the latest publicly available filings, the company reported suspending or winding down research programs and staffing. Data inconclusive based on available public sources regarding any resumption of active R&D or revenue-generating operations.
Strategic Position & Investments
Entheon’s strategic positioning was centered on becoming an early mover in pharmaceutical-grade psychedelic treatments for addiction, differentiating itself from peers focused on depression or PTSD. The company emphasized shorter-acting compounds like DMT as potentially more scalable and clinically manageable than longer-duration psychedelics.
Key investments historically included funding into HaluGen Life Sciences Inc. and internal drug development programs rather than external acquisitions. No completed late-stage clinical trials or commercial partnerships with major pharmaceutical companies were publicly confirmed. Public disclosures indicate that after 2022 the company deprioritized growth initiatives due to liquidity challenges. Data inconclusive based on available public sources regarding current strategic investments or active development pipelines.
Geographic Footprint
Entheon Biomedical Corp. was headquartered in Vancouver, British Columbia, Canada, which served as the center for its corporate management and research coordination. The company’s operational footprint was limited, with no large-scale manufacturing or commercial infrastructure.
The firm previously indicated an intention to operate across North America, particularly in Canada and the United States, due to regulatory pathways and market size for addiction treatments. There is no verified evidence of active operations, facilities, or investments outside North America, and no confirmed international subsidiaries beyond its Canadian corporate structure.
Leadership & Governance
The company was founded and led by entrepreneurs and executives with backgrounds in biotechnology, finance, and emerging therapeutics. Governance followed a typical public micro-cap life sciences structure, with a board of directors overseeing management during its active development phase.
Key executives publicly associated with the company include:
- Timothy Ko – Founder & Chief Executive Officer
- Shawn Singh – Chairman of the Board
- Ryan Beedie – Chief Financial Officer
Publicly available information after 2022 provides limited visibility into current executive involvement or board activity. Data inconclusive based on available public sources regarding present-day leadership structure or governance operations.